These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8002633)

  • 21. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanisms of resistance to DNA topoisomerase II inhibitors].
    Kohno K; Takano H; Kuwano M
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication.
    Snapka RM
    NCI Monogr; 1987; (4):55-60. PubMed ID: 2819732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
    Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
    Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerases of kinetoplastid parasites: why so fascinating?
    Das BB; Sengupta T; Ganguly A; Majumder HK
    Mol Microbiol; 2006 Nov; 62(4):917-27. PubMed ID: 17042788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A model for tumor cell killing by topoisomerase poisons.
    Zhang H; D'Arpa P; Liu LF
    Cancer Cells; 1990 Jan; 2(1):23-7. PubMed ID: 2167111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase inhibitors suppress release of globin sequences into small soluble DNA in erythroblasts.
    Strauss PR
    Prog Clin Biol Res; 1990; 352():249-56. PubMed ID: 2169630
    [No Abstract]   [Full Text] [Related]  

  • 33. Resistance mechanisms to topoisomerase poisons: the application of cell culture methods.
    Baguley BC; Finlay GJ; Ching LM
    Oncol Res; 1992; 4(7):267-74. PubMed ID: 1360275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.
    Chen AY; Yu C; Bodley A; Peng LF; Liu LF
    Cancer Res; 1993 Mar; 53(6):1332-7. PubMed ID: 8383008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase-targeting antitumor agents and drug resistance.
    Takano H; Kohno K; Matsuo K; Matsuda T; Kuwano M
    Anticancer Drugs; 1992 Aug; 3(4):323-30. PubMed ID: 1330080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
    Okada K; Andoh T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1562-7. PubMed ID: 1651683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yeast as a genetic model system for studying topoisomerase inhibitors.
    Nitiss JL
    Adv Pharmacol; 1994; 29B():201-26. PubMed ID: 8996609
    [No Abstract]   [Full Text] [Related]  

  • 38. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
    Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
    J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA topoisomerase inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug resistance associated with altered DNA topoisomerase II.
    Beck WT; Danks MK; Wolverton JS; Kim R; Chen M
    Adv Enzyme Regul; 1993; 33():113-27. PubMed ID: 8395133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.